Leap Therapeutics (LPTX)

• Market cap: $24.2M
• 1 day: -4.34%
• 5 days: -11.24%
• 1 month: -19.81%
• 3 months: 19.26%
• 6 months: 11.84%
• Year to date: -86.71%
• 1 year: -88.34%
• 5 years: -97.77%
• 10 years: -99.46%
• Sector: Healthcare
• Industry: Biotechnology

About: Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

Employees: 52